BioSpace News Archive

BriaCell Therapeutics Corp. is pleased to announce the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD, as well as the addition of Charles Sidman, PhD, MBA, to its scientific advisory board.

Cassava Sciences, Inc., a clinical-stage biotechnology company, announced a potentially significant safety finding based on interim magnetic resonance imaging brain data from Alzheimer’s patients who are enrolled in a Phase 3 clinical trial of simufilam.

In a unique partnership, Boehringer Ingelheim Ltd., St. Joseph’s Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis related to interstitial lung disease.This collaboration marks a significant leap forward in patient-centric care, driven by empathy and understanding.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC) in EU country Latvia.

TriSalus Life Sciences® Inc. announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer 38th Annual Meeting being held November 1-5, 2023, in San Diego, California.

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company’s proposal to harmonize clinical trial designs in the U.S. and Canada for an ongoing Phase 3 study of EB05 (paridiprubart).

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2023 on Wednesday, Nov. 1 at 9 a.m., ET.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing drugs targeting the endocannabinoid system, initially focused on the CB1 receptor to address glaucoma and metabolic conditions, is pleased to report successful results from its Phase 1 clinical trial assessing the safety and pharmacokinetics of SBI-100 Ophthalmic Emulsion (“OE”).

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a leading Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the discovery of a novel function for its lead anticancer injectable drug AccuTOX® in the context of cell-based cancer vaccine engineering.

USAMRIID to study antiviral activity of Claromer technology against national priority biodefense threats